Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Clinical trial NCT05504278 · RECRUITING
Trial details
- NCT number
- NCT05504278
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-20
- Primary completion
- 2025-05-31
- Enrollment
- 144
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.